One fifth of Europe's biopharma firms "at risk of bankruptcy"
This article was originally published in Scrip
The European biotechnology industry is calling for urgent action at both EU and national levels after a new study suggested that a fifth of small European biopharmaceutical companies could be facing bankruptcy by the end of the year as a result of the global financial crisis.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.